Copyright
©The Author(s) 2016.
World J Clin Cases. Feb 16, 2016; 4(2): 49-55
Published online Feb 16, 2016. doi: 10.12998/wjcc.v4.i2.49
Published online Feb 16, 2016. doi: 10.12998/wjcc.v4.i2.49
Figure 1 Basaline features: Psoriasis Area and Severity Index score 11.
5, starting dose of cyclosporine 4 mg/kg per day.
Figure 2 Week 48: Clinical worsening (Psoriasis Area and Severity Index score 22.
8) after reduction cyclosporine therapy.
Figure 3 Treatment with etanercept: At week 12 Psoriasis Area and Severity Index score 16.
2.
Figure 4 Treatment with infliximab: Week 16 Psoriasis Area and Severity Index score 15.
Figure 5 Treatment with adalimumab: Week 12 Psoriasis Area and Severity Index score 22.
4.
Figure 6 Combination therapy with cyclosporine and adalimumab: Week 12 Psoriasis Area and Severity Index score 2.
3.
- Citation: Salvi M, Macaluso L, Luci C, Mattozzi C, Paolino G, Aprea Y, Calvieri S, Richetta AG. Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis C. World J Clin Cases 2016; 4(2): 49-55
- URL: https://www.wjgnet.com/2307-8960/full/v4/i2/49.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v4.i2.49